Cargando…

Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer

OBJECTIVE: The concept of platinum sensitivity and cross-resistance among platinum agents are widely known in the management of recurrent ovarian cancer. The aim of this study was to evaluate two hypotheses regarding the validity of the concept of platinum sensitivity and non-cross-resistance of cis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takekuma, Munetaka, Kuji, Shiho, Tanaka, Aki, Takahashi, Nobutaka, Abe, Masakazu, Hirashima, Yasuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4510334/ https://www.ncbi.nlm.nih.gov/pubmed/26197856 http://dx.doi.org/10.3802/jgo.2015.26.3.185

Ejemplares similares

The relationship between positive peritoneal cytology and the prognosis of patients with FIGO stage I/II uterine cervical cancer
por: Kuji, Shiho, et al.
Publicado: (2014)

Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy
por: Abe, Masakazu, et al.
Publicado: (2015)

Vitamin B12 Deficiency Anemia and Polyneuropathy Due to Chronic Radiation Enteritis
por: Fukuda, Hiroyuki, et al.
Publicado: (2019)

Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity
por: Möltgen, Sophie, et al.
Publicado: (2020)

Phenethylisothiocyanate Potentiates Platinum Therapy by Reversing Cisplatin Resistance in Cervical Cancer
por: Mahapatra, Elizabeth, et al.
Publicado: (2022)

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
por: Nishio, Shin, et al.
Publicado: (2017)

Treatment of Advanced or Recurrent Cervical Cancer with Cisplatin or Cisplatin Containing Regimens: A Cost Effective Analysis
por: Geisler, John P., et al.
Publicado: (2012)

Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer
por: Aoki, Yoichi, et al.
Publicado: (2018)

DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells
por: Martens-de Kemp, Sanne R., et al.
Publicado: (2013)

Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy
por: Zhao, Chong, et al.
Publicado: (2016)

Long-term platinum retention after treatment with cisplatin and oxaliplatin
por: Brouwers, Elke EM, et al.
Publicado: (2008)

Cisplatin-Membrane Interactions and Their Influence on Platinum Complexes Activity and Toxicity
por: Martinho, Nuno, et al.
Publicado: (2019)

Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells.
por: Kondo, S., et al.
Publicado: (1995)

Enhancement of Cisplatin Sensitivity in Human Cervical Cancer: Epigallocatechin-3-Gallate
por: Kilic, Ulkan, et al.
Publicado: (2015)

NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells
por: Tao, Tao, et al.
Publicado: (2017)

Pentoxifylline Sensitizes Cisplatin-Resistant Human Cervical Cancer Cells to Cisplatin Treatment: Involvement of Mitochondrial and NF-Kappa B Pathways
por: Bravo-Cuellar, Alejandro, et al.
Publicado: (2020)

Effects of Cisplatin and its Analogues on the Permeability of Human Erythrocyte Membrane
por: Lu, J.-F., et al.
Publicado: (1995)

Radiosensitizers in cervical cancer. Cisplatin and beyond
por: Candelaria, Myrna, et al.
Publicado: (2006)

Identification of Cisplatin-Binding Proteins Using Agarose Conjugates of Platinum Compounds
por: Karasawa, Takatoshi, et al.
Publicado: (2013)

Mechanisms of Cisplatin-Induced Apoptosis and of Cisplatin Sensitivity: Potential of BIN1 to Act as a Potent Predictor of Cisplatin Sensitivity in Gastric Cancer Treatment
por: Tanida, Satoshi, et al.
Publicado: (2012)

Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.
por: Hettinga, J. V., et al.
Publicado: (1997)

Hymenialdisine is Cytotoxic Against Cisplatin-Sensitive but Not Against Cisplatin-Resistant Cell Lines
por: Abdullah, Nada, et al.
Publicado: (2021)

Cisplatin-resistant HepG2 cell-derived exosomes transfer cisplatin resistance to cisplatin-sensitive cells in HCC
por: Tang, Zuxiong, et al.
Publicado: (2021)

In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
por: Mellish, K. J., et al.
Publicado: (1993)

Cisplatin and its analogues in the treatment of advanced breast cancer: a review.
por: Smith, I. E., et al.
Publicado: (1992)

Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
por: Petrillo, Marco, et al.
Publicado: (2019)

Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin.
por: Stewart, D. J., et al.
Publicado: (1995)

Structural damage of chicken red blood cells exposed to platinum nanoparticles and cisplatin
por: Kutwin, Marta, et al.
Publicado: (2014)

Semen and serum platinum levels in cisplatin‐treated survivors of germ cell cancer
por: Malone, Eoghan R., et al.
Publicado: (2021)

Toll‐like receptor 4 is activated by platinum and contributes to cisplatin‐induced ototoxicity
por: Babolmorad, Ghazal, et al.
Publicado: (2021)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Molecular mechanisms of cisplatin resistance in cervical cancer
por: Zhu, Haiyan, et al.
Publicado: (2016)

Phase II study of adjuvant chemotherapy with paclitaxel and nedaplatin for uterine cervical cancer with lymph node metastasis
por: Takekuma, Munetaka, et al.
Publicado: (2018)

Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells
por: Zhang, Xiaopeng, et al.
Publicado: (2016)

Bixin and fucoxanthin sensitize human lung cancer and cervical cancer cell to cisplatin in vitro
por: Nurcahyanti, Agustina Dwi Retno, et al.
Publicado: (2021)

Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients
por: Saito, Yoshitaka, et al.
Publicado: (2023)

lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer
por: Li, Qing, et al.
Publicado: (2018)

Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids
por: Han, Yi, et al.
Publicado: (2022)

Comments on: Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
por: Batista, Thales Paulo, et al.
Publicado: (2019)

Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin
por: C̆emaz̆ar, M, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_cpkl6i05hsfhtcu0jka21aq2td